Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964658 | 0.78 | MAPK1 (0.55) | MAPK1MCHR1 | |
| SCHEMBL1476882 | 0.76 | MAPK1 (0.52) | MAPK1MCHR1 | |
| SCHEMBL2152830 | 0.76 | MAPK1 (0.52) | MAPK1MCHR1 | |
| SCHEMBL12889635 | 0.76 | MAPK1 (0.52) | MAPK1MCHR1 | |
| SCHEMBL12408484 | 0.74 | MAPK1 (0.50) | MAPK1MCHR1 | |
| SCHEMBL12858882 | 0.74 | MAPK1 (0.50) | MAPK1MCHR1 | |
| SCHEMBL12858877 | 0.74 | MAPK1 (0.50) | MAPK1MCHR1 | |
| SCHEMBL23836753 | 0.73 | MAPK1 (0.44) | MAPK1MCHR1 | |
| SCHEMBL12892667 | 0.72 | — | — | |
| SCHEMBL17992734 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021131834-A1 | COLORED RESIN COMPOSITION | 住友化学株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021131835-A1 | COLORED RESIN COMPOSITION | 住友化学株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | AR, UTS2R, FSHR | MAPK1 2144/4885MCHR1 381/4885 |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | MAPK1 39/4885MCHR1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.